Tarsus to Acquire Alkeus for Up to $1.14 Billion, Securing Stargardt Disease Drug

Paragon Spin-Off Velaris Goes Public Through Reverse Merger With Alaunos

Syndax halts development of Niktimvo for pulmonary fibrosis; shares plunge 17%

BioNTech’s mRNA Cancer Vaccine Misses Primary Endpoint for Progression-Free Survival in Phase 3 Trial

Roche Signs $1.6 Billion Deal With China’s Rona for ALK7 Obesity Drug

Formycon and Zydus’ Keytruda Biosimilar Is First to Be Accepted for FDA Review

Pfizer Signs $500 Million Protein Degrader Deal With Enodia